Current projects

LQ-DMP- Quality of life of COPD patients participating in disease management program
Team:Prof. Dr. Reiner Leidl, PD Dr. Larissa Schwarzkopf, Dr. Florian Kirsch, Boglárka Szentes, Alisa Stöber, Nelli Schneider
Co-operation partner:Dr. Anja Schramm, AOK Bayern
Duration:01.04.2017-31.03.2021; 4 years
Description:The LQ-DMP project includes a postal quality of life survey of all insured persons of the AOK Bayern participating in the Disease Management Program (DMP) COPD as well as the linking and subsequent analysis of the survey data with health insurance data of the AOK Bayern (healthcare utilization data and DMP documentation data). With this information we should be able to identify the interaction between medical care, disease progression and quality of life development of the affected people and identify comprehensive starting points for improved care of COPD patients ('outcome-oriented management'). 
Objectives:Further development of target group specific disease management approaches based on quality of life data from COPD patients.

Exploring the potential for quality of life-oriented patient management in routine care.


In Phase 1 roughly 50.000 participants of the DMP COPD will receive selected quality of life questionnaires (EQ-5D-5L and COPD assessment test) alongside with questions about sociodemographic aspects and about disease history (exacerbations). The participating persons will receive the same questions one year later again in order to examine quality of life developments.

In Phase 2 the primary, the DMP documentation and the routine data will be linked together. Claims data provides information about healthcare utilization and the DMP data about clinical aspects of the disease. The combination of the different data makes it possible to quantify the quality of life effect of medical parameters (e.g. medication coverage, duration of smoking cessation, frequency of exacerbations or impairments in lung function) and to identify driving factors of quality of life in a cross sectional and longitudinal setting. Furthermore it is possible to determine the effect of selected healthcare utilization aspects (e.g. healthcare professionals, rehabilitation or other respiratory therapies) on quality of life and disease progression.

Based on these findings, different patient subgroups with special needs for specific disease management strategies will be identified. The implementation of appropriate approaches will be intensively discussed with medical and insurance experts.

Huber MB, Kurz C, Kirsch F, Schwarzkopf L, Schramm A, Leidl R (2020) The relationship between body mass index and health related quality of life in COPD: real world evidence based on claims and survey data. Respiratory Research 21:291
Kirsch F, Schramm A, Kurz C, Schwarzkopf L Lutter J, Szentes B, Huber M, Leidl R (2020) (2020) Effect of BMI on health care expenditures stratified by COPD GOLD severity grades: Results from the LQ-DMP Study. Respiratory Medicine Nov 02,
Hindelang M, Kirsch F, Leidl R (2020) Effectiveness of non-pharmacological COPD management on health-related quality of life – a systematic review. Expert Reviews of Pharmacoeconomic Outcomes 20(1):79-91
Szentes BL, Schwarzkopf L, Kirsch F, Schramm A, Leidl R (2020) Measuring quality of life in COPD patients: Comparing disease-specific supplements to the EQ-5D-5L. Expert Reviews of Pharmacoeconomic Outcomes 20(5):523–529
Kirsch F, Schramm A, Schwarzkopf L, Lutter J, Szentes B, Huber M, Leidl R (2019) Direct and Indirect Costs of COPD Progression and its Comorbidities in a Structured Disease Management Program: Results from the LQ-DMP Study. Respiratory Research 20(1):15,